WP
JUNO

WealthPLAN Partners’s Juno Therapeutics, Inc. JUNO Stock Holding History

WealthPLAN Partners’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-100
Closed -$3.84K – 1121
2016
Q2 		$3.84K Buy
+100
New +$4.15K ﹤0.01% 2072
2015
Q4 		$4.4K Buy
+100
New +$4.96K ﹤0.01% 1358
2015
Q2 		– Sell
-100
Closed -$6K – 534
2015
Q1 		$6K Buy
+100
New +$4.85K ﹤0.01% 418

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

WealthPLAN Partners's JUNO Position: Q3 2016 in Review

WealthPLAN Partners sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2016, closing a stake of 100 shares — an estimated $3.84K sold.

WealthPLAN Partners first reported a position in JUNO in Q1 2015 and held it in 3 quarters. The position peaked at $6K in Q1 2015. 169 funds tracked by Wall St. Rank hold JUNO as of Q3 2016.

  • WealthPLAN Partners reported no remaining Juno Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • WealthPLAN Partners sold 100 Juno Therapeutics, Inc. shares in Q3 2016, an estimated $3.84K.
  • WealthPLAN Partners first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 3 quarters.
  • WealthPLAN Partners's Juno Therapeutics, Inc. position peaked at $6K in Q1 2015.
  • 169 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2016.

Based on WealthPLAN Partners's 13F filing for Q3 2016, filed 9 Dec 2016.